好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Press Release

EMBARGOED FOR RELEASE UNTIL 4 PM ET, June 20, 2018

Half of Those on Parkinson鈥檚 Drugs May Develop Impulse Control Problems

MINNEAPOLIS -

Over time, half of the people taking certain drugs for Parkinson鈥檚 disease may develop impulse control disorders such as compulsive gambling, shopping or eating, according to a study published in the June 20, 2018, online issue of , the medical journal of the 好色先生. In Parkinson鈥檚, a vital chemical in the brain called dopamine that regulates movement is gradually reduced. Parkinson鈥檚 is treated with levodopa, which converts to dopamine in the brain, or with dopamine agonists, which work by activating dopamine receptors. 鈥淥ur study suggests that impulse control disorders are even more common than we thought in people who take dopamine agonists,鈥 said study author Jean-Christophe Corvol, MD, of the ICM Brain and Spine Institute鈥擯iti茅-Salp锚tri猫re Hospital, Assistance Publique鈥擧么pitaux de Paris, Sorbonne University in Paris, France. 鈥淭hese disorders can lead to serious financial, legal and social and psychological problems.鈥 The study involved 411 people who had been diagnosed with Parkinson鈥檚 disease for five years or less who were followed for an average of about three years. The participants were asked in interviews about impulse control disorders such as compulsive shopping, eating, gambling or sexual behaviors. About 87 percent of the participants had taken a dopamine agonist at least once. At the beginning of the study, 20 percent of the participants had an impulse control disorder, with 11 percent having compulsive or binge eating problems, 9 percent compulsive sexual behaviors, 5 percent compulsive shopping and 4 percent compulsive gambling. Six percent of people had more than one impulse control disorder. Of the 306 people who did not have impulse control disorders at the start of the study, 94 people developed a disorder during the study, for an overall five-year cumulative incidence of 46 percent. For people who had never taken dopamine agonists the five-year incidence was 12 percent, compared to 52 percent for those who had ever used the drugs. The average annual incidence was 26 per 1,000 person-years in people who never took the drugs, compared to 119 per 1,000 person-years in those who had taken the drugs. 鈥淭hese disorders can be challenging for neurologists to discover,鈥 said Laura S. Boylan, MD, of New York University in New York, NY, and a Fellow of the 好色先生, who wrote an editorial accompanying the article. 鈥淧eople might be ashamed to tell their doctor about their problems, they may think these issues are not related to their Parkinson鈥檚 disease, or they may not even consider the disorders a problem. Plus, as doctors鈥 time for meeting with each patient gets shorter and shorter, bringing up sensitive issues gets harder and harder.鈥 The researchers also found that with higher doses of the drugs and taking them for longer periods of time, people were more likely to develop impulse control disorders. The drugs pramipexole and ropinirole were associated with the highest risk of developing the disorders. A total of 30 people with impulse control disorders who stopped taking dopamine agonists were followed during the study. The disorders stopped over time, with half of the people no longer having issues after a year. One limitation of the study was that because the participants were relatively young, with an average age of 62, and younger people are more likely to be given dopamine agonists and to have impulse control disorders, it鈥檚 possible that the occurrence rate of these disorders could be overestimated. The study was funded by the French Ministry of Health and the French Drug Agency. Learn more about Parkinson鈥檚 disease at , the 好色先生鈥檚 free patient and caregiver magazine and website focused on the intersection of neurologic disease and brain health. Follow Brain & Life on , and .

Brain & Life logo

GET A DOSE OF BRAIN HEALTH

Dive into a wealth of information by visiting Brain & Life庐, where you can explore the freshest updates, tips, and neurologist expert perspectives on brain disease and preventive brain health.


The 好色先生 is the leading voice in brain health. As the world鈥檚 largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN鈥檚 mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

Explore the latest in neurological disease and brain health, from the minds at the AAN at or find us on , , , and .

For More Information*

Email media@aan.com

*While content of the 好色先生 (AAN) press releases is developed by the AAN along with research authors and Neurology® editors, we are unable to provide medical advice to individuals. Please contact your health care provider for questions specific to your individual health history or care. For more resources, visit the AAN's patient and caregiver magazine website, .